08:42 AM EDT, 10/31/2025 (MT Newswires) -- Hookipa Pharma ( HOOK ) said Friday that the company has completed its sale of assets related to the HB-400 and HB-500 programs to Gilead Sciences ( GILD ) .

The parties signed an agreement in May, under which Gilead agreed to purchase Hookipa's assets for its HB-400 program, which is developing a treatment of hepatitis B virus, and assets for its HB-500 program, which is developing a treatment for human immunodeficiency virus, Hookipa Pharma ( HOOK ) said.

Shares of Hookipa Pharma ( HOOK ) were up nearly 1%, while shares of Gilead Sciences ( GILD ) were down over 2% in recent Friday premarket activity.